glp 1 agonist side effects What are the of GLP-1 agonists? GLP-1 and Low Blood Pressure:

In addition, 37.0% of people treated with 2.4 mg semaglutide achieved improvements in liver fibrosis with no worsening of steatohepatitis compared to 22.5% on placebo

DPP4 in Diabetic Nephropathy Research suggests that DPP4 may play a role in the receptor axis for advanced glycation end products (RAGE), which is crucial for the development of diabetic nephropathy

However, our clinical experience warns of a need for intensive monitoring and deeper understanding, as their potent efficacy could also inadvertently lead to extreme dietary restriction and weight loss in some patients

Differences also exist within drug classes

Deng, F

Factors such as your baseline metabolic rate, genetic makeup, underlying insulin resistance, hormonal imbalances, and starting weight all influence how strongly and quickly you respond to GLP-1 medications